Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.325 4.25 4.40 4.325 4.325 4.33 15,000 08:00:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -1.0 - 12

Evgen Pharma Share Discussion Threads

Showing 10926 to 10947 of 11425 messages
Chat Pages: Latest  445  444  443  442  441  440  439  438  437  436  435  434  Older
DateSubjectAuthorDiscuss
07/11/2022
15:43
It will be 8p before I get excited Mick1909.
clocktower
07/11/2022
15:31
Yup - it takes a bit of patience to build up a position here
givmesunshine
07/11/2022
14:53
Low liquidity works both ways good news and it will explode
mick1909
07/11/2022
14:26
Nice rise but will only let me sell 150000 shares so dont get too excited yet
mick1909
07/11/2022
14:04
moving back up.
manual dexterity
07/11/2022
13:56
I think it will now take it's natural course, as I believe that the stock was worked over the past weeks to allow a large stake to be built, which will have to be disclosed before very long.

On the other hand there maybe a bid in light of the deal that was done and the potential future earnings.

Do not forget "Juvenescence is making good progress with sourcing naturally-derived sulforaphane, production scale-up and regulatory strategy. It is envisaged that product launch will occur in around two years' time at which point milestone payments of over GBP1m will have been received".

Published 07.12.2021
"BUSINESS DEVELOPMENT

Juvenescence partnership

Our first commercial out-licensing deal signed, with Juvenescence in September 2020, monetises one element of Evgen's sulforaphane technology platform, being the application of our Sulforadex stabilisation technology in the dietary supplement market. This gives a commercialisation timescale considerably shorter than that typical of pharmaceutical development.


They may value the company at many more times it's current value due to the potential that they may have identified, as it is coming up to around one year to launch and at which times payments become due. They may also have made faster progress than we are aware of.

So I suggest it maybe in their interest to purchase the company on the cheap, if not them another business that has identified the undervalued patents etc.

clocktower
07/11/2022
13:17
this is so undervalued at the moment and completely off the radar.. reseached it to death now.. so just good to sit here and hold now..

Abit more detail no the trial on the Stalica website

Targeting 1200 patient trial with recuitment for the biosampling study already started! not hanging around


STALICLA announces first patients enrolled in EU/US multicenter data collection biosampling study
The launch of the STA-B-001 study will accelerate the recruitment of participants for STP1 and STP2 Phase 2 trials. The multicenter trial will also enable deep clinical and biological data collection to strengthen STALICLA’s platform.
Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced first patient visits in its new STA-B-001 clinical observational-biosampling study in Spain and USA.

STALICLA’s unique approach addresses a major weakness in the drug development process for NDDs and neuropsychiatric disorders: behaviour is a terrible biomarker. Thanks to DEPI, a proprietary platform aggregating molecular data and human genetic information, STALICLA pushes the frontier of precision medicine further into precision NDDs. DEPI has already reached validation through the clinical identification of biologically defined subgroups of patients with ASD, ASD-Phenotype 1 and ASD-Phenotype 2, and their respective candidate treatments, STP1 and STP2.

The biosampling clinical study, STA-B-001, is a multicenter, international study involving 12 clinical sites in the USA and Europe and targeting to enrol up to 1’200 patients diagnosed with ASD. This study follows a previous biosampling study conducted at Cincinnati Children Medical Center which permitted the clinical validation of ASD-Phenotype 1 and ASD- Phenotype 2, the first DEPI-identified biological subgroups of patients with ASD.

This new multicenter study will serve multiple purposes including:

the identification of patients eligible for recruitment in STALICLA’s upcoming STP1 and STP2 Phase 2 studies planed in 2023;
the validation of blood-based biomarkers for each subgroup;
the enrichment of STALICLA’s database with comprehensive clinical and biological datasets to support the identification of new subgroup(s) of patients eligible for precision medicine.
STALICLA’s pipeline includes, STP1 is a proprietary fixed dose combination of PDE4/3 inhibitor and NKCC1 antagonist tailored to ASD-Phenotype1. STP2 (SFX-01), is a patented composition of sulforaphane and alpha cyclodextrin, and the only grade of sulforaphane suitable for clinical research and possible approval asmedicine. STALICLA has recently in-licensed SFX-01 rights for NDDs from Evgen Pharma.

givmesunshine
07/11/2022
11:18
Nice bit of blue
givmesunshine
07/11/2022
10:20
Maybe the positive run towards 10p has just started?
clocktower
04/11/2022
23:25
Maybe this share owes me nothing traded it twice might pay 4.2p next week if not then so be it good luck here on your investment it looks good Fundamentally as well TA
mick1909
04/11/2022
15:41
It does not seem that you will be getting them today Mick1909 and may not even ever get them if that is the tops you are willing to pay.

Never know there could be more positive news next week as this seems well oversold imo.

However good luck, we all have targets.

clocktower
04/11/2022
13:27
I mean ask
mick1909
04/11/2022
13:27
Ill re-enter at 4p if the bid gets there?
mick1909
04/11/2022
08:55
YupMe to for now .. I was thinking of adding , but quite heavy wieght in this ..as it is so none for me .. read read the history last night .. not bothered about .1p - got a great future here
givmesunshine
04/11/2022
08:46
I'm out of funds for now. Time for someone else to take the reigns. Will have some fore funds at the end of the month. Amazing how far this has dropped since that amazing RNS. Anyhow good for people like me who have a long term vision to keep stealing then at these levels.
wololol
03/11/2022
14:49
4.49 again to buy time to get the wallet out me thinks.
wololol
03/11/2022
08:29
The pattern continues: Sells starting in the morning as buyers wait to see how low they can obtain more stock, then a trickle of buys and the game continues between bulls and bears, on a daily basis.

More news will knock that game on the head or the sellers run dry.

clocktower
03/11/2022
07:32
Yes - agree , but I can't see us being at the see levels for long - looking downwards we are relatively well protected .. upwards is obvious good as it's not valued for any kind of success even a 10% shot at ASD puts this at 20p yet if you read the history and look a our partnership- see you see that it should be much higher than that "very confident, actually very confident indeed" during the presentation.. just need to sit back and wait GLA
givmesunshine
02/11/2022
18:18
You're doing well W - nice and patient
givmesunshine
02/11/2022
17:59
I know what's coming ;)
wololol
02/11/2022
17:58
See my cheeky 100k at the end
wololol
02/11/2022
14:55
Still more sellers than buyers around.
clocktower
Chat Pages: Latest  445  444  443  442  441  440  439  438  437  436  435  434  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230131 16:48:55